Oscar Health OSCR
- Market cap
- $9.6B
- PE
- 22.3×
- 1y median 47.9×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 0.6×
- EV/EBIT
- 2.3×
- Revenue, 12 months
- $15.3B
- +43% on a year ago
- Net margin
- 3.6%
- Free cash flow yield
- n/m
- a yield above 40% (usually a one-off)
Oscar Health trades at 22.3× trailing earnings. Revenue was $15.3B over the last twelve months, up 43% on a year earlier with a 4% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.4B+47% | $1.4B+44% | $2.1B+46% | $2.2B+46% | $2.4B+68% | $2.4B+67% | $3B+42% | $2.9B+29% | $3B+23% | $2.8B+17% | $4.6B+53% | $4.9B+70% | |
| SG&A | $325.9M+315% | $364.2M+380% | $394.2M−1% | $435.2M+29% | $460.4M+41% | $465.8M+28% | $482.8M+23% | $534.5M+23% | $521.6M+13% | $511M+10% | $706.2M+46% | $691.1M+29% |
| −$58.2M−70% | −$145.5M−35% | $185.6M | $67.8M | −$48.4M−17% | −$147.7M+2% | $297.1M+60% | −$230.5M | −$129.3M+167% | −$333.7M+126% | $704.1M+137% | $388.6M | |
| Interest expense | $6.1M+0% | $6.2M+1% | $5.9M−4% | $6M−2% | $5.8M−5% | $6M−3% | $6M+2% | $5.8M−2% | $6.9M+18% | −$1.1M | $5.4M−10% | $4.7M−20% |
| Pre-tax income | −$64.8M−67% | −$150.6M−34% | $178.5M | $60.9M | −$52.3M−19% | −$153.7M+2% | $288.2M+62% | −$233.5M | −$139.3M+166% | −$352.7M+130% | $698.8M+143% | $383M |
| $915K | −$806K+13% | $996K−51% | $4.6M+298% | $2.1M+127% | −$404K−50% | $12.7M+1176% | −$5M | −$1.8M | −$247K−39% | $19.8M+56% | $21.2M | |
| Net income | −$65.4M−66% | −$150M−34% | $177.4M | $56.2M | −$54.6M−17% | −$153.5M+2% | $275.3M+55% | −$228.4M | −$137.4M+152% | −$352.6M+130% | $679M+147% | $361.8M |
| −$0.29−68% | −$0.66−37% | $0.62 | $0.20 | −$0.22−24% | −$0.62−6% | $0.92+48% | −$0.89 | −$0.53+141% | −$1.25+102% | $2.07+125% | $1.10 | |
| 223.1M+5% | 227.1M+6% | 293.8M+35% | 304M+39% | 243.1M+9% | 248.2M+9% | 305.9M+4% | 255.5M−16% | 259.3M+7% | 283.1M+14% | 329.8M+8% | 333.4M+31% |
EPS, diluted: 6 periods, Q4 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 6 periods, Q4 FY20 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Healthcare Plans nearest Oscar Health's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| OSCROscar Health | $9.6B | 22.3× | 47.9× | n/m | 0.6× | +43% | 3.6% |
| CNCCentene | $34.7B | n/m | 20.7× | 15.0× | 0.2× | +14% | −2.5% |
| HUMHumana | $50.7B | 39.9× | 20.7× | 33.7× | 0.3× | +18% | 0.9% |
| ALHCAlignment Healthcare | $1.7B | 42.4× | 124× | n/m | 0.4× | +37% | 0.9% |
| TRUPTrupanion | $1.3B | 55.3× | 60.0× | n/m | 0.8× | +12% | 1.5% |
| CICigna | $81.1B | 12.7× | 16.1× | 9.7× | 0.3× | +8% | 2.3% |
| ELVElevance Health | $95.4B | 19.6× | 17.6× | 16.1× | 0.5× | +6% | 2.5% |
| Peer median | $42.7B | 39.9× | 20.7× | 15.5× | 0.4× | +13% | 1.2% |
Investors who own it
Investors we follow who held Oscar Health at the end of Jun 30, 2026, from their 13F filings.
- Polen CapitalPolen Capital0.0% of portfolionew
More on Oscar Health
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Where it ranks
- #4of 202Healthcare stocks with the lowest EV/EBIT
- #1of 11Health insurers with the highest profit margins
- #1of 10Health insurers with the lowest EV/EBIT
- #2of 11Health insurers with the fastest revenue growth
- #8of 11Health insurers with the lowest price to sales ratio
Its groups
About
- Industry
- Medical - Healthcare Plans
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .